Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Active, not recruiting · NCT03546426 · Registry updated 2024-10-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies | Disease Attributes, Disease Progression, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, adenoma, epithelial neoplasm, lung disorder, lung neoplasm, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2024-10-01 | NCT03546426 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 20 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) | Meldola | Italy | 3 |